BACKGROUND AND PURPOSE Our purpose was to assess the presence of lupus anticoagulant and fibrinolytic system abnormalities in young patients with stroke. METHODS We studied 33 consecutive ischemic patients aged < 50 years. Lupus anticoagulant was screened by four different coagulation tests, and the fibrinolytic system was studied by analyzing tissue plasminogen activator antigen and plasmino...

BACKGROUND AND PURPOSE Early thrombolytic therapy with recombinant tissue-type plasminogen activator is a theoretically attractive approach to the treatment of acute focal cerebral ischemia. In preparation for a larger multicenter trial, three centers piloted a protocol for a randomized, double-blind, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator begun wi...

Background: Treatment with tissue plasminogen activator (TPA) for acute stroke requires intensive care of the patient. The risk thrombolytic therapy and need rapid interventions make it clear that nursing role during this time is crucial. aim: This study aims to assess nurses' Performance regarding monitoring patients during administration Tissue Plasminogen Activator drug. Study design...

Fibrinolytic system In addition to the mechanisms which achieve haemostasis by the formation of fibrin-stabilized platelet plugs, man possesses an efficient system designed to remove unwanted or excessive fibrin. The enzyme which cleaves fibrin into soluble degradation products is termed plasmin (EC 3.4.4.14); it is present in the circulation as a zymogen known as plasminogen. The activation of...

Stem cells have been successfully used for the treatment of critical limb ischemia (CLI). We conducted a clinical trial to determine the feasibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of CLI. Unexpectedly, two diabetic patients developed peripheral microthrombosis. This adverse effect, which contrasts with the reported antithrombotic propert...

PURPOSE To report the use of intracameral tissue plasminogen activator to dissolve fibrinous membranes and break posterior synechiae in patients with acute HLA-B27-positive iridocyclitis with impending pupillary block. METHODS Two patients with severe acute fibrinous iridocyclitis and seclusio pupillae were identified. Because of the concern of impending pupillary block, intracameral tissue p...

The secretion of tissue plasminogen activator ft-PA). urokinase (u-PA) and their inhibitors by the human leukemia cell line K562 was examined. K562 cells normally secrete both t -PA and u-PA in a ratio of 3:1 . After addition of 10 or 1 ng/mL phorbol myristate acetate (PMA) to K562 cells. a marked decrease in enzymatic activity is observed in the medium. However. when t-PA antigen rather than a...

We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasminogen activator and streptokinase. We occluded the middle cerebral arteries of 137 rabbits with radiolabeled blood clots and administered tissue plasminogen activator (n=49), streptokinase («=40), or saline (n=48) at various times after embolization. We assessed the rate of thrombolysis and cere...

PURPOSE Prostate cancer cell motility and invasion have been linked to the up-regulated signaling of epidermal growth factor receptor and urokinase-type plasminogen activator receptor. We analyzed the expression of serum urokinase-type plasminogen activator receptor and epidermal growth factor receptor in the serum of patients with clinical suspicion of prostate cancer to evaluate the possible ...